Novozymes

This page will close down soon – follow our new page @novonesis

Novozymes is now Novonesis. In January 2024, we merged with Chr. Hansen.

We are 10,000 people worldwide who are passionate about the power of biosolutions to help solve humanity's biggest challenges. ❤️

What is a #biosolution?

Earlier this week, we started the era of #biosolutions and a new beginning as @novonesis.

Today, legacy Novozymes announced its last full year announcement, delivering solid results with an organic sales growth of 5% and an EBIT margin of 25.4% before special items for the financial year 2023.

CEO Ester Baiget of Novonesis commented on the results: “Legacy Novozymes has leveraged its strengths of a well-diversified portfolio, unique production capabilities and broad market presence to deliver strong growth in a volatile market. Biosolutions hold the key to some of the world’s biggest challenges, and the growth in 2023 confirms our continued trajectory to growth and the demand and strong momentum."

Looking towards the journey ahead, she adds: “We have already started a new chapter as Novonesis. The combination between two great companies is a reality, and we are set to further accelerate growth and to develop transformative biosolutions as the leading global biosolutions partner. We have gathered the brightest minds, and together with my more than 10,000 colleagues, we will unlock the limitless potential of biosolutions. A special thank you to all our stakeholders for your support. We are ready to lead the new era of biosolutions.”

Learn more about the results of the 2023 financial year for legacy Novozymes in the illustrations below or at this link: novonesis.com/en/news/legacy…

#financialresults #newbeginning

It's time for the era of #biosolutions. Learn about biology's tiny but mighty agents of change that are at the heart of @novonesis.

#newbeginning #novonesis

Welcome to the era of #biosolutions. Welcome to @novonesis.

The proposed combination of Novozymes and @Chr_Hansen is now successfully completed. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 employees worldwide and expertise that spans more than 30 different industries.

Our CEO Ester Baiget says: “Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions.”

Cees de Jong, our Chair of the Board of Directors, adds his perspective: “I am pleased to witness the realization of the Novozymes and Chr. Hansen combination, creating a true global biosolutions leader. We will continue to create powerful biosolutions for our customers and partners based on our more than 100 years of innovation and application expertise. Together, we will serve as a growth partner to our customers; a value creator to our shareholders; and a company that has a significant, positive impact on society and the planet. Novonesis builds on a shared heritage of sustainability leadership and will keep leading the way.”

Learn more: novonesis.com/en/news/combin…

Follow @novonesis to keep updated on our future journey as a new company.

#novonesis #newbeginning #biosolutions